ArticleBMC nephrology2025
Abelmoschus manihot alleviates insulin resistance in diabetic kidney disease through attenuation of inflammation.
Article in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundEmerging evidence implicates insulin resestance (IR) and chronic inflammation as interdependent drivers of diabetic kidney disease (DKD) progression. This study aims to investigate whether Abelmoschus manihot can concurrently ameliorate both pathological pathways in DKD patients.
methodsThis study enrolled 94 biopsy-proven DKD patients (45 controls, 49 manihot group) with Homeostatic model assessment of insulin resistance (HOMA-IR) ≥ 5 and high-sensitivity C-reactive protein (hsCRP) ≥ 1 mg/L from China-Japan Friendship Hospital (2012–2023). All patients received standard care medications, and those in the manihot group were treated with Abelmoschus Manihot for 12 months. Participants were followed up every 3 months for a total of 1 year. Changes in HOMA-IR, hsCRP, 24-hour urine protein excretion (24-h-UPE), and estimated glomerular filtration rate (eGFR) from baseline during follow-up were assessed. Additionally, differences in 24-h-UPE, eGFR, and major cardiovascular and cerebrovascular events between the groups after treatment were evaluated. Adverse events and laboratory test abnormalities were also recorded.
resultsA total of 94 biopsy-proven DKD patients were included. Among them, 45 patients received standard care (control group), while 49 additionally took standard care plus Abelmoschus Manihot. The results revealed a statistically significant reduction in 24-h-UPE in the manihot group compared to the control group at 6 months (− 232.9 vs. − 145.8 mg, P = 0.04) and beyond. Since the 9-month follow-ups, the manihot group exhibited a significantly slower eGFR decline (-3.2 vs. -4.7 mL/min/1.73m2, P < 0.05). Additionally, IR in the manihot group was significantly reduced in both within- and between-groups (compared to the control), and hsCRP also exhibited analogous findings. In the manihot group, a significant positive correlation was observed between the decrease in hsCRP and the decrease in HOMA-IR, with P-value < 0.01. In contrast, no such significant correlation was observed in the control group, where the P-value was 0.1. No significant adverse events or laboratory test abnormalities were observed.
conclusionThis study suggests that in biopsy-confirmed DKD patients, Abelmoschus Manihot may provide additional benefits to standard care, including improvements in IR and inflammatory markers. However, longitudinal studies are needed to examine the causal association.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.